The United Kingdom has legislated against corruption in various forms since the late 19th Century, this itself drawing on a longer tradition in British law. The Bribery Act 2010 is a recent and landmark addition to the legislative environment in the UK for corruption.
Within the health sector, pharmaceuticals stands out as sub-sector that is particularly prone to corruption. There are abundant examples globally that display how corruption in the pharmaceutical sector endangers positive health outcomes, resulting in the possibility of fatal consequences.
Managing third party risk: Only as strong as your weakest link provides practical advice on addressing the challenges of managing third party bribery risk. Although aimed at larger companies, the content may also be helpful to small and medium enterprises (SMEs) as well as regulators, prosecuting agencies and professional advisers.
As heads of government gather in London for the International Anti-Corruption Summit to discuss next steps in tackling corruption worldwide, leaders from business and civil society tell us why they think more needs to be done.
More statements can be read at www.anticorruption-manifesto.org